Back

JPP · Lens · Subconjunctival Bevacizumab for Recurrent Conjunctival Pyogenic Granuloma

PDF

Article · Volume 10, Issue 1 · pp. 42–44

Subconjunctival Bevacizumab for Recurrent Conjunctival Pyogenic Granuloma

Nirupama Kasturi1, Tharini Senthamizh1, Hanuman Srinivas Bheemanathi1, K. Ramesh Babu2

  1. 1Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India.
  2. 2Department of Pathology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India.

Abstract

A 45-year-old male presented with a pyogenic granuloma of the bulbar conjunctiva of the left eye following a stick injury. It was a benign friable, hyperplastic, vascular lesion comprised of inflammatory cells and lobular capillary proliferation. The differential diagnosis includes squamous papillomas, hemangiomas, suture granulomas, and ocular surface tumors, such as squamous cell carcinoma and amelanotic melanoma. Conventional treatment includes topical corticosteroids and surgical excision. Treatment of recurrent lesions with cryotherapy, electrocautery, topical antimetabolites, and plaque irradiation has been described. We present a case of recurrent pyogenic granuloma successfully treated with two subconjunctival bevacizumab injections. The patient developed three recurrences after excision at a peripheral hospital after which he was successfully treated with excision and adjuvant subconjunctival bevacizumab 2.5 mg/0.1 ml injection. This case highlights the novel use of bevacizumab for recurrent pyogenic granuloma.

Keywords: Bevacizumab; conjunctival mass; pyogenic granuloma

The full text of this article is available as a PDF. Open the PDF.